|Dr. Peter M. Hecht||CEO & Director||72.73k||N/A||1964|
|Dr. Mark G. Currie||Pres & Chief Scientific Officer||317.88k||N/A||1955|
|Dr. Andreas Busch Ph.D.||Chief Innovation Officer||373.96k||N/A||1963|
|Mr. William Huyett||Chief Financial Officer||N/A||N/A||1956|
|Mr. Mark Gaffney||Head of External Innovation & Corp. Devel.||N/A||N/A||N/A|
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.’s ISS Governance QualityScore as of December 6, 2019 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 1; Compensation: 7.